You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

Details for Patent: 7,737,112

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 7,737,112 protect, and when does it expire?

Patent 7,737,112 protects KYPROLIS and is included in one NDA.

This patent has sixty-eight patent family members in twenty-one countries.

Summary for Patent: 7,737,112

Scope and claims summary:

Title:	Composition for enzyme inhibition
Abstract:	Compositions comprising one or more practically insoluble proteasome inhibitors and a cyclodextrin, particularly a substituted cyclodextrin, substantially increase the solubility of these proteasome inhibitors and facilitate their administration. Such compositions optionally comprise a buffer. Methods of treatment using such compositions are also disclosed.
Inventor(s):	Lewis; Evan R. (Pacifica, CA), Ho; Mark Nguyen (San Jose, CA), Fonseca; Fabiana N. (New York, NY)
Assignee:	Onyx Therapeutics, Inc. (South San Francisco, CA)
Application Number:	11/299,265
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,737,112
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound;

Drugs Protected by US Patent 7,737,112

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Onyx Pharms Amgen	KYPROLIS	carfilzomib	POWDER;INTRAVENOUS	202714-003	Jun 7, 2018		RX	Yes	No	7,737,112	⤷ Subscribe	Y				⤷ Subscribe
Onyx Pharms Amgen	KYPROLIS	carfilzomib	POWDER;INTRAVENOUS	202714-002	Jun 3, 2016		RX	Yes	No	7,737,112	⤷ Subscribe	Y				⤷ Subscribe
Onyx Pharms Amgen	KYPROLIS	carfilzomib	POWDER;INTRAVENOUS	202714-001	Jul 20, 2012	AP	RX	Yes	Yes	7,737,112	⤷ Subscribe	Y				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 7,737,112

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E499109	⤷ Subscribe
Australia	2005243140	⤷ Subscribe
Australia	2005243168	⤷ Subscribe
Australia	2005313975	⤷ Subscribe
Brazil	PI0510802	⤷ Subscribe
Canada	2565407	⤷ Subscribe
Canada	2566839	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.